Objective To detect the consistency of EGFR
mutations in
pleural effusion in terminal
non-small cell lung cancer(NSCLC)
patients by amplification refractory
mutation system- polymeric
chain reaction (
ARMS-
PCR).
Methods Pleural effusion from 44 cases with advanced NSCLC were collected.
DNA was extract-ed from a part of
pleural effusion,and EGFR gene18,19,20,and 2 l
exons mutations were detected by
ARMS-
PCR amplification. The left part of
pleural effusion was used for the pathological microscopic examination of the embedding and to evaluate the feasibility of
pleural effusion direct
detection.Part of the case results were compared with
tissue or
pleural effusion at the same
time. Results The
mutation rate of EGFR
detection in
pleural effusion was 54.5%,including 19-del(50.0%)and 21-L858R(50.0%);75.0% of
pleural effusion sediment was morpho-logically diagnosed with
adenocarcinoma and EGFR
mutation rate was 27.3% in
pleural effusion with no
tumor cell. The consistent rate was 72.7% in 22 cases of
pleural effusion and
tissue and that was 50.0% in 16 cases of
pleural effusion and
plasma.The comparison between
pleural effusion and
organizations and
plasma test results was statisti-cally significant(P < 0.05).(P < 0.05).Conclusions
EGFR gene mutation rate in
pleural effusion is lower than that in
tumor tissue specimens in terminal NSCLC
patients and
tumor tissue is still the best test specimens.